logo
Plus   Neg
Share
Email

Surface Oncology Inks SRF813 Licensing Deal With GSK For $85 Mln Upfront - Quick Facts

Surface Oncology Inc. (SURF), a clinical-stage immuno-oncology company, said Thursday it has entered into an agreement for GlaxoSmithKline Plc. (GSK.L,GSK) to exclusively license worldwide development and commercial rights to Surface Oncology's preclinical program SRF813.

SRF813 is a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells. SRF813 is currently in IND-enabling studies with an IND planned for 2021.

Under the terms of the deal, GSK will make an upfront payment of $85 million. In addition, Surface Oncology may receive up to an additional $730 million in future milestone payments and will also be eligible to receive tiered royalties on global net sales.

Following the close of the GSK license agreement, together with current cash and cash equivalents, Surface Oncology projects cash runway sufficient to fund its operations through 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
RELATED NEWS
Follow RTT